

Non-Small Cell Lung Cancer (NSCLC)

**A Study of Atezolizumab in Participants With Programmed Death -
Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small
Cell Lung Cancer**

Trial Status
Completed

Trial Runs In
19 Countries

Trial Identifier
NCT02031458 2013-003330-32
GO28754

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02031458 2013-003330-32 GO28754
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No